Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 06 04:00PM ET
174.40
Dollar change
-2.53
Percentage change
-1.43
%
IndexNDX, S&P 500 P/E15.76 EPS (ttm)11.07 Insider Own0.77% Shs Outstand144.90M Perf Week-3.74%
Market Cap25.41B Forward P/E10.30 EPS next Y16.93 Insider Trans-0.04% Shs Float144.59M Perf Month-4.33%
Income1.62B PEG3.24 EPS next Q3.44 Inst Own89.22% Short Float2.12% Perf Quarter-14.54%
Sales9.23B P/S2.75 EPS this Y11.51% Inst Trans-0.56% Short Ratio2.70 Perf Half Y-20.63%
Book/sh112.28 P/B1.55 EPS next Y3.11% ROA5.72% Short Interest3.07M Perf Year-29.86%
Cash/sh11.66 P/C14.96 EPS next 5Y4.86% ROE10.47% 52W Range170.71 - 268.30 Perf YTD-32.60%
Dividend Est.- P/FCF13.05 EPS past 5Y-18.05% ROI7.60% 52W High-35.00% Beta-0.06
Dividend TTM- Quick Ratio0.80 Sales past 5Y-4.53% Gross Margin67.77% 52W Low2.16% ATR (14)4.62
Dividend Ex-Date- Current Ratio1.26 EPS Y/Y TTM9.71% Oper. Margin22.96% RSI (14)33.78 Volatility2.86% 2.42%
Employees7570 Debt/Eq0.41 Sales Y/Y TTM-3.98% Profit Margin17.50% Recom1.81 Target Price254.56
Option/ShortYes / Yes LT Debt/Eq0.30 EPS Q/Q665.41% Payout0.00% Rel Volume1.60 Prev Close176.93
Sales Surprise1.29% EPS Surprise8.15% Sales Q/Q-2.44% EarningsOct 30 BMO Avg Volume1.14M Price174.40
SMA20-4.96% SMA50-8.67% SMA200-18.00% Trades Volume1,818,540 Change-1.43%
Date Action Analyst Rating Change Price Target Change
Oct-31-24Downgrade Morgan Stanley Overweight → Equal-Weight $285 → $204
Oct-10-24Resumed Raymond James Mkt Perform
Feb-14-24Reiterated Needham Buy $305 → $300
Feb-14-24Downgrade Wells Fargo Overweight → Equal Weight $315 → $240
Jan-24-24Downgrade UBS Buy → Neutral $311 → $276
Dec-20-23Resumed Cantor Fitzgerald Overweight $311
Dec-07-23Upgrade Raymond James Mkt Perform → Outperform $283
Sep-06-23Initiated HSBC Securities Buy $360
Jul-27-23Initiated Scotiabank Sector Outperform $327
Jul-24-23Reiterated UBS Buy $346 → $335
Nov-05-24 09:40AM
Nov-04-24 09:35AM
Nov-01-24 08:00AM
Oct-31-24 08:03PM
10:51AM
03:07AM Loading…
03:07AM
Oct-30-24 07:30PM
04:27PM
02:01PM
01:46PM
01:45PM
09:30AM
08:05AM
07:38AM
07:28AM
07:18AM Loading…
07:18AM
07:07AM
07:02AM
06:54AM
06:15AM
Oct-29-24 06:00PM
05:03PM
05:03PM
08:00AM
05:54AM
Oct-28-24 09:16AM
08:30AM
Oct-26-24 08:15PM
Oct-24-24 07:30AM
Oct-23-24 10:01AM
09:40AM Loading…
09:40AM
03:19AM
Oct-22-24 07:30AM
Oct-20-24 04:28PM
02:20PM
Oct-19-24 11:19AM
Oct-17-24 12:12PM
10:11AM
Oct-16-24 03:02PM
08:45AM
Oct-10-24 12:10PM
12:01PM
Oct-09-24 07:30AM
Oct-08-24 08:52AM
07:30AM
Oct-07-24 09:40AM
Oct-03-24 09:25AM
Oct-02-24 06:52AM
Oct-01-24 08:46PM
Sep-26-24 10:37AM
Sep-24-24 11:05AM
08:19AM
06:33AM
01:00AM
Sep-23-24 09:00PM
Sep-20-24 08:00AM
Sep-16-24 09:40AM
01:52AM
Sep-13-24 06:55AM
Sep-12-24 03:32PM
07:30AM
Sep-06-24 12:53PM
07:00AM
Sep-05-24 12:00PM
Sep-04-24 10:43AM
08:15AM
07:30AM
Aug-26-24 10:15AM
Aug-22-24 01:45PM
12:33PM
09:40AM
07:38AM
05:10AM
Aug-20-24 09:00AM
Aug-15-24 12:45PM
Aug-11-24 09:05AM
Aug-09-24 09:00AM
Aug-02-24 09:40AM
Aug-01-24 04:00PM
03:26PM
01:32PM
12:25PM
11:49AM
11:23AM
09:37AM
09:30AM
08:05AM
07:28AM
06:50AM
Jul-31-24 02:33PM
10:33AM
09:00AM
07:33AM
Jul-30-24 05:15PM
09:15AM
07:30AM
Jul-29-24 01:13PM
11:53AM
10:33AM
05:30AM
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grogan JaneHead of ResearchNov 01 '24Option Exercise0.006950695Nov 04 04:39 PM
Singhal PriyaHead of DevelopmentAug 30 '24Option Exercise0.001,66806,554Sep 05 06:00 AM
Singhal PriyaHead of DevelopmentSep 03 '24Sale204.2243188,0195,316Sep 05 06:00 AM
Singhal PriyaOfficerSep 03 '24Proposed Sale204.2243188,019Sep 03 01:00 PM
Keeney AdamHead of Corporate DevelopmentMay 01 '24Option Exercise0.009380938May 03 08:00 PM
Singhal PriyaHead of DevelopmentApr 02 '24Sale213.099319,8174,886Apr 03 08:24 PM
Murphy NicoleHead of Pharm Ops and TechApr 01 '24Option Exercise0.0024009,751Apr 03 08:11 PM
Singhal PriyaHead of DevelopmentFeb 22 '24Sale221.2326257,9624,886Feb 26 07:54 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 16 '24Option Exercise0.005,037052,506Feb 21 09:39 PM
Gregory GingerEVP, Human ResourcesFeb 16 '24Option Exercise0.004,704014,341Feb 21 09:36 PM
Izzar RachidHead of Global Product Strat.Feb 16 '24Option Exercise0.002,017010,014Feb 21 09:33 PM
Kramer RobinChief Accounting OfficerFeb 16 '24Option Exercise0.001,34506,354Feb 21 09:31 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 16 '24Option Exercise0.006,720020,692Feb 21 09:29 PM
Murphy NicoleHead of Pharm Ops and TechFeb 16 '24Option Exercise0.001,26009,624Feb 21 09:28 PM
Singhal PriyaHead of DevelopmentFeb 16 '24Option Exercise0.001,20805,429Feb 21 09:27 PM
Singhal PriyaHead of DevelopmentFeb 16 '24Sale221.4910823,9215,148Feb 21 09:27 PM
Rowinsky Eric KDirectorFeb 15 '24Buy222.54455101,25620,629Feb 20 09:13 PM
Gregory GingerEVP, Human ResourcesFeb 09 '24Option Exercise0.002,158011,778Feb 13 06:14 PM
Singhal PriyaHead of DevelopmentFeb 09 '24Option Exercise0.001,21205,309Feb 13 06:06 PM
Singhal PriyaHead of DevelopmentFeb 12 '24Sale239.45419100,3304,516Feb 13 06:06 PM
Murphy NicoleHead of Pharm Ops and TechFeb 09 '24Option Exercise0.002,27209,529Feb 13 06:04 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 09 '24Option Exercise0.003,257017,555Feb 13 06:03 PM
Kramer RobinChief Accounting OfficerFeb 09 '24Option Exercise0.0083305,523Feb 13 06:01 PM
Izzar RachidHead of Global Product Strat.Feb 09 '24Option Exercise0.001,51509,081Feb 13 06:00 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 09 '24Option Exercise0.002,575050,021Feb 13 05:56 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 08 '24Option Exercise0.002,190048,101Feb 09 08:16 PM
Gregory GingerEVP, Human ResourcesFeb 08 '24Option Exercise0.001,635010,118Feb 09 08:14 PM
Izzar RachidHead of Global Product Strat.Feb 08 '24Option Exercise0.002,04308,187Feb 09 08:11 PM
Kramer RobinChief Accounting OfficerFeb 08 '24Option Exercise0.0078804,943Feb 09 08:06 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 08 '24Option Exercise0.002,335015,063Feb 09 08:03 PM
Murphy NicoleHead of Pharm Ops and TechFeb 08 '24Option Exercise0.002,10107,895Feb 09 08:01 PM
Singhal PriyaHead of DevelopmentFeb 01 '24Option Exercise0.001,82805,292Feb 05 06:38 PM
Singhal PriyaHead of DevelopmentFeb 02 '24Sale245.93634155,9204,097Feb 05 06:38 PM
Singhal PriyaHead of DevelopmentDec 08 '23Option Exercise0.0042603,780Dec 12 05:06 PM
Singhal PriyaHead of DevelopmentDec 11 '23Sale248.0011027,2803,464Dec 12 05:06 PM
Kramer RobinChief Accounting OfficerDec 08 '23Option Exercise0.0035104,325Dec 12 05:02 PM